2,3-Bis(4-fluorophenyl)quinoxalin-6-amine | 937724-67-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 2,3-Bis(4-fluorophenyl)quinoxalin-6-amine
• CAS: 937724-67-9
• 化学式: C₂₀H₁₃F₂N₃
• 分子量: 333.34
• InChiKey: SREXRPMDWPJZCW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  25
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  51.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2,3-Bis(4-fluorophenyl)quinoxalin-6-amine 在 盐酸 、 copper(l) iodide 、 potassium carbonate 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 8.0h， 生成 2,3-bis(4-fluorophenyl)-N-((1-p-tolyl-1H-1,2,3-triazol-4-yl)methyl)quinoxalin-6-amine
  参考文献：
  名称：

  Chandra Shekhar, Adimulam; Venkat Lingaiah, Boddupally Pedda; Shanthan Rao, Pamulaparthy, Letters in drug design and discovery, 2015, vol. 12, # 5, p. 393 - 407

  摘要：

  DOI：
• 作为产物：
  描述：

  4,4'-二氟苯偶酰 在 palladium 10% on activated carbon 、 氢氟酸 、 一水合肼 作用下， 以 乙醇 、 水 为溶剂， 反应 8.0h， 生成 2,3-Bis(4-fluorophenyl)quinoxalin-6-amine
  参考文献：
  名称：

  Emergence of pyrido quinoxalines as new family of antimalarial agents

  摘要：

  A series of novel N-alkyl dihydro pyrido quinoxaline derivatives were synthesized using Gould-Jacobs reaction and evaluated their antimalarial activity in vitro against chloroquine sensitive (3D7) and drug resistant (Dd2) strains of Plasmodium falciparum. Among the compounds tested, 10 compounds were more potent than their structural standard analog ciprofloxacin, including 2 derivatives 5e and 5h, which showed 3.3-7.4 times more potency than ciprofloxacin against both the parasite strains. The results are encouraging and a lead molecule may emerge which is useful alone or in combination therapy. (C) 2014 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2014.03.010

文献信息

• [EN] QUINOXALINE COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS À BASE DE QUINOXALINE ET LEURS UTILISATIONS
  申请人：MILLENNIUM PHARM INC

  公开号：WO2015161142A1

  公开（公告）日：2015-10-22

  This invention provides compounds of formula I and subsets thereof: wherein T, J, R, R4, Rq, o, RA, and RB and subsets thereof are as described in the specification. The compounds are inhibitors of NAMPT and are thus useful for treating cancer, inflammatory conditions, or T-cell mediated autoimmune disease.

  这项发明提供了公式I及其子集的化合物：其中T、J、R、R4、Rq、o、RA和RB以及其子集如规范中所述。这些化合物是NAMPT的抑制剂，因此可用于治疗癌症、炎症性疾病或T细胞介导的自身免疫疾病。
• Quinoxaline compounds and uses thereof
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：US10144742B2

  公开（公告）日：2018-12-04

  This invention provides compounds of formula I and subsets thereof: wherein T, J, R, R4, Rq, o, RA, and RB and subsets thereof are as described in the specification. The compounds are inhibitors of NAMPT and are thus useful for treating cancer, inflammatory conditions, or T-cell mediated autoimmune disease.

  本发明提供了式 I 及其子集的化合物：其中 T、J、R、R4、Rq、o、RA 和 RB 及其子集如说明书所述。这些化合物是 NAMPT 的抑制剂，因此可用于治疗癌症、炎症或 T 细胞介导的自身免疫性疾病。
• Quinoxalinylurea derivatives as a novel class of JSP-1 inhibitors
  作者：Li Zhang、Beiying Qiu、Bing Xiong、Xin Li、Jingya Li、Xin Wang、Jia Li、Jingkang Shen

  DOI：10.1016/j.bmcl.2007.01.094

  日期：2007.4

  A series of quinoxalinylurea-based inhibitors are synthesized and shown to be the novel and potent inhibitors against Jnk Stimulatory Phosphatase-1 (JSP-1), which is a special member of dual-specificity protein phosphatase (DSP) family. Biological assay and computational modeling studies showed the compounds were reversible and noncompetitive inhibitors of JSP-1. JSP-1 inhibitors may be useful for the treatment of inflammatory, vascular, neurodegenerative, metabolic, and oncological diseases in humans associated with dysfunctional Jnk signaling. (c) 2007 Elsevier Ltd. All rights reserved.
• QUINOXALINE COMPOUNDS AND USES THEREOF
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：EP3131881A1

  公开（公告）日：2017-02-22